APA (7th ed.) Citation

DY, R., SY, L., JJ, H., YH, L., N, L., XJ, Q., . . . RH, X. (2026). Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.05.003

Chicago Style (17th ed.) Citation

DY, Ruan, et al. "Preclinical Characterization and Phase I Results of TQB2102, a First-in-class HER2 Biparatopic Antibody-drug Conjugate, in Patients with Advanced Solid Tumors." Annals of Oncology : Official Journal of the European Society for Medical Oncology 2026. https://doi.org/10.1016/j.annonc.2026.05.003.

MLA (9th ed.) Citation

DY, Ruan, et al. "Preclinical Characterization and Phase I Results of TQB2102, a First-in-class HER2 Biparatopic Antibody-drug Conjugate, in Patients with Advanced Solid Tumors." Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2026, https://doi.org/10.1016/j.annonc.2026.05.003.